Viewpoint: What Is Reasonable and Necessary for People Living with AD after the FDA Approves a Treatment?

J Prev Alzheimers Dis. 2023;10(3):344-345. doi: 10.14283/jpad.2023.74.

Authors

R S Doody¹, S Skerjanec

Affiliation

¹ Rachelle S. Doody, F. Hoffman-LaRoche Ltd., Basel, Switzerland, [email protected].

PMID: 37357269
DOI: 10.14283/jpad.2023.74

No abstract available

MeSH terms

Drug Approval*
Humans
United States
United States Food and Drug Administration